Markets Earnings Screener Watchlist

Fundamentals and filings are sourced from SEC EDGAR. Market data, ownership and analyst consensus are sourced from Nasdaq. Written analysis is generated by metir from those sources and the linked reporting.

All information is provided for informational purposes only. It is not investment, financial, tax or legal advice, is not a recommendation to buy or sell any security, and is not intended for trading purposes. Data may be delayed or incomplete.

Biogen Inc. Stock Price: Quote, Financials, Forecast & News (BIIB)

Markets open

Biogen Inc.

BIIB · Nasdaq

Overview Financials Earnings Holders Historical Data Analysis

Symbol: BIIB
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: Nasdaq

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

Analyst Consensus

Buy

35 analysts

$209

Current

—

Low

$239

Average

—

High

Average target implies +14.20% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Zoetis Inc.ZTS · NYSE$74.09

2.56%

Royalty Pharma plc Class A Ordinary Shares RPRX · NASDAQ-GS$57.660.31%

BeOne Medicines Ltd. American Depositary SharesONC · Nasdaq$332.352.89%

Waters CorporationWAT · NYSE$400.981.24%

$208.85+$0.400.19%

As of: Aug 5, 2:40 PM

Prev Close: $208.45
Market Cap: $30.86B
Open: —
Trailing P/E: —
Day Range: $212.18 - $208.50
52W Range: $219.72 - $127.00
Forward P/E: —
EPS: —
Volume: 114.62K
Dividend Yield: —

Notable Price Movement

Weekly movement commentary will appear here once it has been generated for this company.

Stories & Analysis

Why Supernus Pharmaceuticals Stock Topped the Market Today

The Motley Fool · 2d ago

IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook

Zacks · 6d ago

Why Biogen Stock Topped the Market Today

The Motley Fool · Jul 29

Q2 Earnings Season in Full Swing

Zacks · Jul 29

Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised

Zacks · Jul 29 Investors Await Fed Decision Today

Zacks · Jul 29 Biogen Q2 Earnings Call Highlights

MarketBeat · Jul 29 Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks · Jul 29

Beta

—

Avg Volume

1.25M